4Moving Biotech is a clinical-stage biopharmaceutical company founded in 2020.
We are committed to develop first-in-class breakthrough therapies for the millions of patients suffering from osteoarthritis (OA) in the world.
4Moving Biotech’s primary focus is the clinical development of a disease modifying drug for osteoarthritis: 4P004. Our aim is to provide a long-term solution for the high unmet medical need of osteoarthritis.
4Moving Biotech is a subsidiary of 4P-Pharma, an innovation accelerator biotech company.
Capitalizing on a training course through research with a PhD in Biology of Aging, coupled with a MBA, Revital Rattenbach has made a mark in the lineage of seasoned biotech entrepreneurs.
Driven by a deep ambition to bring discoveries from academic research to the patient, Revital has forged a profile of serial creator through 3 entrepreneurial adventures of which she is at the origin.
The first - Adstem - spin-off from Paris VI University focused on new therapeutic approaches to activate adult stem cells; the second - Pharmaseed Europe - still in activity - articulates its expertise in pharmaceutical development from discovery to regulatory preclinical, and the latest created 7 years ago now - 4P-Pharma - is specialized in the repositioning of drugs for diseases related to aging.
Francis Berenbaum is the co-founder, Chief Executive Officer & Chief Medical Officer of 4Moving Biotech. He is the chairman of 4P-Pharma’s Scientific Advisory Board.
Pr Berenbaum is the Head of the Department of Rheumatology at the Saint-Antoine Hospital (AP-HP) and Professor of Rheumatology at Sorbonne University, in Paris (France). He also leads the research team “Metabolic diseases and age-related joint diseases” (INSERM UMRS 938), focusing on the discovery of mediators involved in osteoarthritis progression that could be therapeutic targets. His team is at the origin of 4Moving Biotech’s lead product, 4P004, which has been accompanied by the French TTO, SATT Lutech.
Pr. Berenbaum is a worldwide recognized key opinion leader for osteoarthritis, he has indeed been president of the OARSI (OsteoArthritis Research Society International) in 2009-2011 and President of the French society of rheumatology (2015-2016). He is also member of several international rheumatology associations, such as the EULAR (European League Against Rheumatology) and the ACR (American College of Rheumatology).
